一项评估 Odevixibat 对胆道闭锁儿童的长期疗效和安全性的开放标签扩展研究 (BOLD-EXT)
一项评估 Odevixibat (A4250) 对胆道闭锁患儿的长期疗效和安全性的开放标签扩展研究 (BOLD-EXT)
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia
研究概览
详细说明
This is a Phase 3, multi-center, open-label extension study to evaluate the long-term efficacy and safety of odevixibat in patients with Biliary Atresia (BA). Patients who completed treatment in the A4250-011 BOLD study and meet eligibility criteria for Study A4250-016 (BOLD-EXT) can participate. The duration of the treatment period is 104 weeks, followed by a 4-week Safety Follow-up Period. Patients who wish to continue receiving odevixibat after 104 weeks can remain on treatment in the optional extension period (OEP).
Up to 180 patients will be enrolled at approximately 70 sites in the North America, Europe, the Middle East and Asia-Pacific.
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
-
Guangdong、中国
- Guangzhou Women And Childrens Medical Center
-
Shanghai、中国
- Children's Hospital of Fudan University
-
-
-
-
-
Montreal、加拿大
- CHU Sainte-Justine
-
Toronto、加拿大
- The Hospital for Sick Children
-
-
-
-
-
Ankara、土耳其(türkiye)
- Hacettepe İhsan Doğramacı Children's Hospital
-
Antalya、土耳其(türkiye)
- Akdeniz University Medical Faculty
-
Istanbul、土耳其(türkiye)
- Istanbul University Istanbul Medical Faculty Hospital
-
-
-
-
-
Berlin、德国
- Charité - Universitätsmedizin Berlin
-
Tübingen、德国
- University Children´s Hospital Tuebingen
-
-
-
-
-
Bergamo、意大利
- ASST Papa Giovanni XXIII
-
Padova、意大利
- Azienda Ospedaliera di Padova
-
-
-
-
-
Auckland、新西兰、1023
- Starship Child Health, Te Whatu Ora - Health New Zealand
-
-
-
-
-
Le Kremlin-Bicêtre、法国
- Bicêtre Hospital
-
-
-
-
-
Warsaw、波兰
- Instytut Pomnik-Centrum Zdrowia Dziecka
-
-
-
-
-
Parkville、澳大利亚、3052
- Royal Children's Hospital
-
-
-
-
Colorado
-
Aurora、Colorado、美国、80045
- Children's Hospital Colorado
-
-
Georgia
-
Atlanta、Georgia、美国、30322
- Children's Healhcare of Atlanta- Emory University school of medicine
-
-
Indiana
-
Indianapolis、Indiana、美国、46202
- Indiana University school of Medicine
-
-
Massachusetts
-
Boston、Massachusetts、美国、02115
- Boston Children's Hospital
-
-
Missouri
-
Kansas City、Missouri、美国、64108
- Children's Mercy Hospital and Clinics
-
-
New York
-
New York、New York、美国、10016
- Hassenfeld Children's Hospital at NYU Langone
-
New York、New York、美国、10032
- Columbia University Medical Center New York Presbyterian Morgan Stanley-Komansky Childrens Hospital
-
The Bronx、New York、美国、10467
- The Childrens Hospital at Montefiore Albert Einstein School of Medicine
-
-
Ohio
-
Cincinnati、Ohio、美国、45229
- Cincinnati Children's Hospital Medical Center
-
-
Washington
-
Seattle、Washington、美国、98105
- Seattle Children's Hospital
-
-
-
-
-
Groningen、荷兰
- University Medical Center Groningen
-
-
-
-
-
Barcelona、西班牙
- Hospital Universitari Vall d'Hebron
-
-
-
-
-
Seoul、韩国
- Seoul National University Childrens Hospital
-
-
-
-
-
Kota Bharu、马来西亚
- Hospital Raja Perempuan Zainab II
-
Kuala Lumpur、马来西亚、59100
- University Malaya Medical Centre
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Completion of the 104-week Treatment Period of Study A4250-011
- Signed informed consent by caregiver
Exclusion Criteria:
- Patients who were not compliant with study drug treatment or procedures in Study A4250-011 as per the investigator's discretion
- Any conditions or abnormalities which, in the opinion of the investigator, may compromise the safety of the patient, or interfere with the patient participating in or completing the study
- Known hypersensitivity to any components of odevixibat
- Patients who are scheduled for a liver transplant or are likely to require a liver transplant in the immediate future based on the investigator's judgment
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Odevixibat (A4250)
Capsules for oral administration once daily for 104 weeks. |
Odevixibat is a small molecule inhibitor of the ileal bile acid transporter (IBAT).
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
存活且未接受肝移植的患者比例
大体时间:从基线到第 104 周
|
从基线到第 104 周
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
血清胆汁酸的变化
大体时间:从基线到第 26、52、78 和 104 周
|
从基线到第 26、52、78 和 104 周
|
|
|
身高变化
大体时间:从基线到第 26、52、78 和 104 周
|
从基线到第 26、52、78 和 104 周
|
|
|
体重变化
大体时间:从基线到第 26、52、78 和 104 周
|
从基线到第 26、52、78 和 104 周
|
|
|
任何哨兵事件发生的时间
大体时间:从基线到第 104 周
|
从基线到第 104 周
|
|
|
Change in aspartate aminotransferase (AST) to platelet ratio index (APRI) score
大体时间:From baseline to Week 104
|
The APRI (aspartate aminotransferase to platelet ratio index) score estimates the severity of liver fibrosis. A higher score indicates a greater amount of scarring (fibrosis) in the liver.
|
From baseline to Week 104
|
|
Change in Fibrosis-4 (Fib-4) score
大体时间:From baseline to Week 104
|
The Fib-4 score provides an estimate of the amount of scarring (fibrosis) in the liver. A higher score indicates a greater amount of scarring in the liver.
|
From baseline to Week 104
|
|
Change in mid-arm circumference
大体时间:From Baseline to Weeks 26, 52, 78 and 104
|
Measure of growth |
From Baseline to Weeks 26, 52, 78 and 104
|
|
Change in pediatric end-stage liver disease (PELD) score
大体时间:From Baseline to Weeks 26, 52, 78 and 104
|
The PELD (pediatric end-stage liver disease) score is a measure of disease severity. PELD scores can range from a negative value (such as -10) to high numbers (such as 45). A higher score indicates more severe disease. |
From Baseline to Weeks 26, 52, 78 and 104
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- A4250-016
- 2022-501090-39-00 (克蒂斯)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.
Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
IPD 共享时间框架
Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.
IPD 共享访问标准
Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.